Tidepath

Amylin drugs

CagriSema

Also called cagrilintide-semaglutide, cagrilintide and semaglutide

Semaglutide, the drug in Wegovy and Ozempic, paired with an amylin drug in one weekly injection178.

Status
Not approved by the FDA as of October 20264; Novo Nordisk filed for approval in December 20251.
How it's taken
By injection

What it is

CagriSema is two drugs in one weekly injection under the skin1. One is semaglutide, the GLP-1 drug in Wegovy and Ozempic78. GLP-1 is a hormone your gut releases when you eat15. The other is cagrilintide, a long-acting version of amylin, a hormone from the pancreas that brings on a feeling of fullness112. Each drug has led to weight loss on its own in trials, and CagriSema gives them together3. Because both come together in set amounts, it's called a fixed-dose combination1.

What makes it distinct

CagriSema is two separate drugs given together, not one molecule1. REDEFINE 1, a phase 3 trial, compared the pair with each drug alone and with placebo2.

What the evidence shows

Two phase 3 trials, REDEFINE 1 and REDEFINE 2, each lasted 68 weeks and were published in 202523. REDEFINE 1 enrolled 3,417 adults without diabetes who had obesity, or overweight plus at least one weight-related condition2. REDEFINE 2 enrolled 1,206 adults with type 2 diabetes and overweight or obesity3. In both, people on CagriSema lost more weight than people on placebo (a dummy injection)23. Stomach and gut side effects, such as nausea, vomiting, diarrhoea and constipation, were common, and mostly mild to moderate and short-lived23. In two phase 3 trials in type 2 diabetes, REIMAGINE 1 and REIMAGINE 3, HbA1c, a blood test for average blood sugar over the past few months, fell more on CagriSema than on placebo910. In REIMAGINE 3, CagriSema was added to long-acting (basal) insulin10.

Open questions

  • The FDA's decision. Novo Nordisk filed in December 2025 and said it expected the FDA to review the application in 20261.
  • Effects on heart attacks, strokes and deaths from heart or blood vessel disease. REDEFINE 3, a trial in 7,076 people with heart or blood vessel disease, is testing this and hasn't reported1113.
  • Effects on weight over longer periods. A phase 3 trial measuring weight at 104 weeks is still running14.

Sources

  1. Novo Nordisk company announcement, 18 December 2025: Novo Nordisk files for FDA approval of CagriSema
  2. Garvey WT et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med 2025;393:635-647. PMID 40544433
  3. Davies MJ et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med 2025;393:648-659. PMID 40544432
  4. FDA: Novel Drug Approvals for 2026 (content current as of 10/20/2026)
  5. WEGOVY (semaglutide) injection and tablet, FDA prescribing information (DailyMed, revised 6/2026)
  6. OZEMPIC (semaglutide) injection, FDA prescribing information (DailyMed, revised 5/2026)
  7. Aroda VR et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1). Lancet Diabetes Endocrinol 2026;14(8):649-661. PMID 42251860
  8. Rosenstock J et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3). Lancet 2026;408:38-51. PMID 42251856
  9. Cavender MA et al. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J 2026 (online ahead of print). PMID 42838477
  10. Lau DCW et al. Once-weekly cagrilintide for weight management (phase 2). Lancet 2021;398:2160-2172. PMID 34798060
  11. ClinicalTrials.gov NCT05669755: REDEFINE 3
  12. ClinicalTrials.gov NCT06780449: Long-term Efficacy and Safety of CagriSema Once Weekly Versus Placebo in Participants With Obesity
  13. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)

More in Amylin drugs